Loading...
GNS logo

Genus plcLSE:GNS Stock Report

Market Cap UK£1.8b
Share Price
UK£26.70
n/a
1Y36.9%
7D0%
Portfolio Value
​
View

Genus plc

LSE:GNS Stock Report

Market Cap: UK£1.8b

Genus (GNS) Stock Overview

Produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. More details

GNS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of 2.5% per year for the next 3 years

Large one-off items impacting financial results


GNS Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

GNS logo
Genus

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

Key Takeaways Growth in the porcine division and strategic partnerships in China are expected to enhance Genus's revenue and earnings. Expansion in the bovine segment through acquisitions and programs like VAP is projected to improve profit margins and financial stability.
View narrative
UK£31.67
FV
15.7% undervalued intrinsic discount
4.10%
Revenue growth p.a.
82
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
GNS logo
Genus

Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability

Key Takeaways Structural shifts towards alternative proteins and increased scrutiny on animal genetics threaten Genus's market relevance, revenue growth, and long-term earnings stability. Heavy R&D dependence and complex regulation expose Genus to margin compression, strained cash flows, and volatile profitability amid rising global compliance costs.
View narrative
UK£25.5
FV
4.7% overvalued intrinsic discount
3.84%
Revenue growth p.a.
16
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
GNS logo
Genus

Growing Global Protein Demand Will Accelerate Livestock Genetics

Key Takeaways Faster-than-expected regulatory progress and strategic partnerships position Genus for significant revenue and margin expansion, especially in the Chinese market. Leadership in advanced genetics and deepening presence in emerging markets strengthen Genus' premium pricing and future growth opportunities.
View narrative
UK£35
FV
23.7% undervalued intrinsic discount
6.92%
Revenue growth p.a.
6
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
4.2k
users have viewed this narrative
15users have liked this narrative
0users have commented on this narrative
82users have followed this narrative
US$21.53
68.3% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Genus plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genus
Historical stock prices
Current Share PriceUK£26.70
52 Week HighUK£32.29
52 Week LowUK£15.48
Beta0.85
1 Month Change-13.17%
3 Month Change7.01%
1 Year Change36.92%
3 Year Change-8.50%
5 Year Change-46.02%
Change since IPO1,877.78%

Recent News & Updates

Recent updates

Calculating The Fair Value Of Genus plc (LON:GNS)

Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)

Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Estimating The Fair Value Of Genus plc (LON:GNS)

Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)

Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued

Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
User avatar

Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position

Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

The Price Is Right For Genus plc (LON:GNS)

Jun 16
The Price Is Right For Genus plc (LON:GNS)

Estimating The Fair Value Of Genus plc (LON:GNS)

Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

Mar 25
Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Nov 03
We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Shareholder Returns

GNSGB BiotechsGB Market
7D0%-0.3%-0.6%
1Y36.9%26.7%19.0%

Return vs Industry: GNS exceeded the UK Biotechs industry which returned 30.9% over the past year.

Return vs Market: GNS exceeded the UK Market which returned 21% over the past year.

Price Volatility

Is GNS's price volatile compared to industry and market?
GNS volatility
GNS Average Weekly Movement5.6%
Biotechs Industry Average Movement8.4%
Market Average Movement5.0%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.8%

Stable Share Price: GNS has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: GNS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19943,190JK Kokkewww.genusplc.com

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand.

Genus plc Fundamentals Summary

How do Genus's earnings and revenue compare to its market cap?
GNS fundamental statistics
Market capUK£1.79b
Earnings (TTM)UK£47.50m
Revenue (TTM)UK£672.00m
37.6x
P/E Ratio
2.7x
P/S Ratio

Is GNS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNS income statement (TTM)
RevenueUK£672.00m
Cost of RevenueUK£402.40m
Gross ProfitUK£269.60m
Other ExpensesUK£222.10m
EarningsUK£47.50m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 10, 2026

Earnings per share (EPS)0.71
Gross Margin40.12%
Net Profit Margin7.07%
Debt/Equity Ratio46.4%

How did GNS perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
46%
Payout Ratio

Does GNS pay a reliable dividends?

See GNS dividend history and benchmarks
When do you need to buy GNS by to receive an upcoming dividend?
Genus dividend dates
Ex Dividend DateMar 05 2026
Dividend Pay DateMar 27 2026
Days until Ex dividend9 days
Days until Dividend pay date13 days

Does GNS pay a reliable dividends?

See GNS dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/13 02:16
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genus plc is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert ChantryBerenberg
Alexander JonesBofA Global Research
Matthew John YatesBofA Global Research